Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bor-Sheng Ko

Showing results (131-140 of 156) with videos related to

Pageof 16
Sort By:
American Journal of Hematology|October 12, 2013
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolutionChien-Chin Lin, Hsin-An Hou, Wen-Chien Chou, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 30, 2025
Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World AnalysisTai-Chung Tseng, Yu-Sung Chang, Xavier Cheng-Hong Tsai, et al.
Blood Cancer Journal|September 8, 2018
GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemiaFeng-Ming Tien, Hsin-An Hou, Cheng-Hong Tsai, et al.
American Journal of Hematology|March 2, 2023
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemiaMin-Yen Lo, Xavier Cheng-Hong Tsai, Chien-Chin Lin, et al.
Blood Cancer Journal|May 19, 2025
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutationsSao-Chih Ni, Chi-Yuan Yao, Xavier Cheng-Hong Tsai, et al.
American Journal of Hematology|October 16, 2013
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progressionHsin-An Hou, Yuan-Yeh Kuo, Jih-Luh Tang, et al.
American Journal of Hematology|May 22, 2014
IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patientsYi-Tsung Yang, Hsin-An Hou, Chieh-Yu Liu, et al.
Blood Cancer Journal|January 22, 2024
Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutationsFeng-Ming Tien, Chi-Yuan Yao, Xavier Cheng-Hong Tsai, et al.
Haematologica|May 19, 2018
Concomitant <i>WT1</i> mutations predict poor prognosis in acute myeloid leukemia patients with double mutant <i>CEBPA</i>Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, et al.
Oncotarget|January 27, 2016
Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemiaHsin-An Hou, Chieh-Yu Liu, Yuan-Yeh Kuo, et al.
Pageof 16

Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
American Journal of Hematology|October 12, 2013
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolutionChien-Chin Lin, Hsin-An Hou, Wen-Chien Chou, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 30, 2025
Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World AnalysisTai-Chung Tseng, Yu-Sung Chang, Xavier Cheng-Hong Tsai, et al.
Blood Cancer Journal|September 8, 2018
GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemiaFeng-Ming Tien, Hsin-An Hou, Cheng-Hong Tsai, et al.
American Journal of Hematology|March 2, 2023
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemiaMin-Yen Lo, Xavier Cheng-Hong Tsai, Chien-Chin Lin, et al.
Blood Cancer Journal|May 19, 2025
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutationsSao-Chih Ni, Chi-Yuan Yao, Xavier Cheng-Hong Tsai, et al.
American Journal of Hematology|October 16, 2013
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progressionHsin-An Hou, Yuan-Yeh Kuo, Jih-Luh Tang, et al.
American Journal of Hematology|May 22, 2014
IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patientsYi-Tsung Yang, Hsin-An Hou, Chieh-Yu Liu, et al.
Blood Cancer Journal|January 22, 2024
Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutationsFeng-Ming Tien, Chi-Yuan Yao, Xavier Cheng-Hong Tsai, et al.
Haematologica|May 19, 2018
Concomitant <i>WT1</i> mutations predict poor prognosis in acute myeloid leukemia patients with double mutant <i>CEBPA</i>Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, et al.
Oncotarget|January 27, 2016
Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemiaHsin-An Hou, Chieh-Yu Liu, Yuan-Yeh Kuo, et al.
Pageof 16